Recursion Q3 revenue misses estimates, net loss widens

Reuters

Nov 05

<a href="https://laohu8.com/S/RXRX">Recursion</a> Q3 revenue misses estimates, net loss widens

Overview

Recursion Q3 operating revenue misses analyst expectations
Net loss for Q3 widens, missing analyst estimates
Achieved $30 mln milestone from Roche and Genentech for microglial immune cells map

Outlook

Recursion expects cash runway to extend through 2027 without additional financing
Company anticipates over $100 mln in milestone payments by end of 2026

Result Drivers

MILESTONE PAYMENT - Achieved $30 mln milestone from Roche and Genentech for microglial immune cells map

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Operating Revenue	Miss	$4.98 mln	$17 mln (6 Analysts)
Q3 Net Income	Miss	-$162.25 mln	-$146.90 mln (3 Analysts)
Q3 Pretax Profit	Miss	-$162.25 mln	-$128.90 mln (1 Analyst)
Q3 Operating Income		-$172.20 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is $6.50, about 23.1% above its November 4 closing price of $5.00

Press Release: ID:nGNXgQ3S5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581266227"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581266227\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581266227?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 19:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581266227","market":"us","top_or_hot":-1,"title":"Recursion Q3 revenue misses estimates, net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/RXRX\">Recursion</a> Q3 revenue misses estimates, net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Recursion Q3 operating revenue misses analyst expectations</p></li><li><p>Net loss for Q3 widens, missing analyst estimates</p></li><li><p>Achieved $30 mln milestone from Roche and Genentech for microglial immune cells map</p></li></ul><p><span>Outlook</span></p><ul><li><p>Recursion expects cash runway to extend through 2027 without additional financing</p></li><li><p>Company anticipates over $100 mln in milestone payments by end of 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>MILESTONE PAYMENT - Achieved $30 mln milestone from Roche and Genentech for microglial immune cells map</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Operating Revenue</p></td><td><p>Miss</p></td><td><p>$4.98 mln</p></td><td><p>$17 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Miss</p></td><td><p>-$162.25 mln</p></td><td><p>-$146.90 mln (3 Analysts)</p></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td><p>Miss</p></td><td><p>-$162.25 mln</p></td><td><p>-$128.90 mln (1 Analyst)</p></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$172.20 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 6 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is $6.50, about 23.1% above its November 4 closing price of $5.00</p></li></ul><p>Press Release: <span>ID:nGNXgQ3S5</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recursion Q3 revenue misses estimates, net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecursion Q3 revenue misses estimates, net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 19:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/RXRX\">Recursion</a> Q3 revenue misses estimates, net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Recursion Q3 operating revenue misses analyst expectations</p></li><li><p>Net loss for Q3 widens, missing analyst estimates</p></li><li><p>Achieved $30 mln milestone from Roche and Genentech for microglial immune cells map</p></li></ul><p><span>Outlook</span></p><ul><li><p>Recursion expects cash runway to extend through 2027 without additional financing</p></li><li><p>Company anticipates over $100 mln in milestone payments by end of 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>MILESTONE PAYMENT - Achieved $30 mln milestone from Roche and Genentech for microglial immune cells map</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Operating Revenue</p></td><td><p>Miss</p></td><td><p>$4.98 mln</p></td><td><p>$17 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Miss</p></td><td><p>-$162.25 mln</p></td><td><p>-$146.90 mln (3 Analysts)</p></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td><p>Miss</p></td><td><p>-$162.25 mln</p></td><td><p>-$128.90 mln (1 Analyst)</p></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$172.20 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 6 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is $6.50, about 23.1% above its November 4 closing price of $5.00</p></li></ul><p>Press Release: <span>ID:nGNXgQ3S5</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4611","symbol_name":"AI医疗","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH0IP:1","article_id":"2581266227","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581266227","pubTimestamp":1762342770,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Recursion Q3 revenue misses estimates, net loss widensOverviewRecursion Q3 operating revenue misses analyst expectationsNet loss for Q3 widens, missing analyst estimatesAchieved $30 mln milestone from","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4611":"AI医疗","RXRX":"Recursion Pharmaceuticals, Inc.","BK4609":"英伟达持仓股","BK4539":"次新股","BK4139":"生物科技","BK4548":"巴美列捷福持仓"},"translate_title":"递归第三季度收入未达预期，净亏损扩大","themeId":"e0b11eb1759d2fa3a59526eca8ac097c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":0.9},"content_text":"Recursion Q3 revenue misses estimates, net loss widensOverviewRecursion Q3 operating revenue misses analyst expectationsNet loss for Q3 widens, missing analyst estimatesAchieved $30 mln milestone from Roche and Genentech for microglial immune cells mapOutlookRecursion expects cash runway to extend through 2027 without additional financingCompany anticipates over $100 mln in milestone payments by end of 2026Result DriversMILESTONE PAYMENT - Achieved $30 mln milestone from Roche and Genentech for microglial immune cells mapKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Operating RevenueMiss$4.98 mln$17 mln (6 Analysts)Q3 Net IncomeMiss-$162.25 mln-$146.90 mln (3 Analysts)Q3 Pretax ProfitMiss-$162.25 mln-$128.90 mln (1 Analyst)Q3 Operating Income-$172.20 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 6 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is $6.50, about 23.1% above its November 4 closing price of $5.00Press Release: ID:nGNXgQ3S5For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}